Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)

Conditions:   Non-small Cell Lung Cancer;   Hepatocellular Carcinoma Interventions:   Drug: Nivolumab;   Drug: BMS-813160;   Drug: BMS-986253 Sponsors:   Icahn School of Medicine at Mount Sinai;   Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials